Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix

T. Uno, H. Ito, J. Itami, T. Sato, S. Minoura, S. Yasuda, T. Aruga, K. Isobe, Naoyuki Shigematsu, A. Kubo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with cervical cancer are subject to postoperative adjuvant therapy if the histopathologic examination reveals parametrial involvement. This study evaluated the patterns of failure in patients with pathologic parametrial invasion (pT2b) treated with adjuvant pelvic irradiation. Between April 1985 and March 1997, 45 patients with pT2b cervical cancer were treated with postoperative pelvic irradiation. The median age was 52 years. Preoperative clinical stages were stage Ib in 8 patients, IIa in 4, and IIb in 33. Twenty-three patients had lymph node metastasis. The median total dose of whole pelvic radiation therapy was 50 Gy. Occurrence of pelvic failure or distant metastasis according to the nodal status was examined. None of the 22 patients without lymph node metastasis developed distant metastasis. Among the 23 node-positive patients, 6 developed distant metastasis as an initial failure site. The 5-year overall survival of the entire group was 78%. The actuarial distant metastasis-free rates at 5 years were 73% and 100% for those with and without pelvic lymph node metastasis, respectively (P = 0.016). Results support previous evidence for chemoradiation in patients with pelvic lymph node metastasis. However, it appears that the role of systemic chemotherapy for node-negative pT2b patients is yet to be established.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume12
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Cervix Uteri
Carcinoma
Neoplasm Metastasis
Lymph Nodes
Uterine Cervical Neoplasms
Radiotherapy
Drug Therapy
Survival

Keywords

  • Carcinoma
  • Irradiation
  • Lymph node metastasis
  • Parametrium
  • Uterine cervix

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix. / Uno, T.; Ito, H.; Itami, J.; Sato, T.; Minoura, S.; Yasuda, S.; Aruga, T.; Isobe, K.; Shigematsu, Naoyuki; Kubo, A.

In: International Journal of Gynecological Cancer, Vol. 12, No. 2, 2002, p. 187-191.

Research output: Contribution to journalArticle

Uno, T. ; Ito, H. ; Itami, J. ; Sato, T. ; Minoura, S. ; Yasuda, S. ; Aruga, T. ; Isobe, K. ; Shigematsu, Naoyuki ; Kubo, A. / Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix. In: International Journal of Gynecological Cancer. 2002 ; Vol. 12, No. 2. pp. 187-191.
@article{ba0b0bb40ddd4a57a508c56fa5cf9e34,
title = "Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix",
abstract = "Patients with cervical cancer are subject to postoperative adjuvant therapy if the histopathologic examination reveals parametrial involvement. This study evaluated the patterns of failure in patients with pathologic parametrial invasion (pT2b) treated with adjuvant pelvic irradiation. Between April 1985 and March 1997, 45 patients with pT2b cervical cancer were treated with postoperative pelvic irradiation. The median age was 52 years. Preoperative clinical stages were stage Ib in 8 patients, IIa in 4, and IIb in 33. Twenty-three patients had lymph node metastasis. The median total dose of whole pelvic radiation therapy was 50 Gy. Occurrence of pelvic failure or distant metastasis according to the nodal status was examined. None of the 22 patients without lymph node metastasis developed distant metastasis. Among the 23 node-positive patients, 6 developed distant metastasis as an initial failure site. The 5-year overall survival of the entire group was 78{\%}. The actuarial distant metastasis-free rates at 5 years were 73{\%} and 100{\%} for those with and without pelvic lymph node metastasis, respectively (P = 0.016). Results support previous evidence for chemoradiation in patients with pelvic lymph node metastasis. However, it appears that the role of systemic chemotherapy for node-negative pT2b patients is yet to be established.",
keywords = "Carcinoma, Irradiation, Lymph node metastasis, Parametrium, Uterine cervix",
author = "T. Uno and H. Ito and J. Itami and T. Sato and S. Minoura and S. Yasuda and T. Aruga and K. Isobe and Naoyuki Shigematsu and A. Kubo",
year = "2002",
doi = "10.1046/j.1525-1438.2002.01092.x",
language = "English",
volume = "12",
pages = "187--191",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix

AU - Uno, T.

AU - Ito, H.

AU - Itami, J.

AU - Sato, T.

AU - Minoura, S.

AU - Yasuda, S.

AU - Aruga, T.

AU - Isobe, K.

AU - Shigematsu, Naoyuki

AU - Kubo, A.

PY - 2002

Y1 - 2002

N2 - Patients with cervical cancer are subject to postoperative adjuvant therapy if the histopathologic examination reveals parametrial involvement. This study evaluated the patterns of failure in patients with pathologic parametrial invasion (pT2b) treated with adjuvant pelvic irradiation. Between April 1985 and March 1997, 45 patients with pT2b cervical cancer were treated with postoperative pelvic irradiation. The median age was 52 years. Preoperative clinical stages were stage Ib in 8 patients, IIa in 4, and IIb in 33. Twenty-three patients had lymph node metastasis. The median total dose of whole pelvic radiation therapy was 50 Gy. Occurrence of pelvic failure or distant metastasis according to the nodal status was examined. None of the 22 patients without lymph node metastasis developed distant metastasis. Among the 23 node-positive patients, 6 developed distant metastasis as an initial failure site. The 5-year overall survival of the entire group was 78%. The actuarial distant metastasis-free rates at 5 years were 73% and 100% for those with and without pelvic lymph node metastasis, respectively (P = 0.016). Results support previous evidence for chemoradiation in patients with pelvic lymph node metastasis. However, it appears that the role of systemic chemotherapy for node-negative pT2b patients is yet to be established.

AB - Patients with cervical cancer are subject to postoperative adjuvant therapy if the histopathologic examination reveals parametrial involvement. This study evaluated the patterns of failure in patients with pathologic parametrial invasion (pT2b) treated with adjuvant pelvic irradiation. Between April 1985 and March 1997, 45 patients with pT2b cervical cancer were treated with postoperative pelvic irradiation. The median age was 52 years. Preoperative clinical stages were stage Ib in 8 patients, IIa in 4, and IIb in 33. Twenty-three patients had lymph node metastasis. The median total dose of whole pelvic radiation therapy was 50 Gy. Occurrence of pelvic failure or distant metastasis according to the nodal status was examined. None of the 22 patients without lymph node metastasis developed distant metastasis. Among the 23 node-positive patients, 6 developed distant metastasis as an initial failure site. The 5-year overall survival of the entire group was 78%. The actuarial distant metastasis-free rates at 5 years were 73% and 100% for those with and without pelvic lymph node metastasis, respectively (P = 0.016). Results support previous evidence for chemoradiation in patients with pelvic lymph node metastasis. However, it appears that the role of systemic chemotherapy for node-negative pT2b patients is yet to be established.

KW - Carcinoma

KW - Irradiation

KW - Lymph node metastasis

KW - Parametrium

KW - Uterine cervix

UR - http://www.scopus.com/inward/record.url?scp=0036255191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036255191&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2002.01092.x

DO - 10.1046/j.1525-1438.2002.01092.x

M3 - Article

VL - 12

SP - 187

EP - 191

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -